iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Adding a second active pharmaceutical ingredient (API) supplier improves continuity only when it is a genuinely qualified, usable source. A second company name is not automatically a second independent supply path: both suppliers may rely on the same starting-material producer, intermediate site, testing laboratory, broker, port, utility or regional manufacturing cluster.
Qualify the specific manufacturing site and its quality system, confirm analytical and process comparability, define responsibilities in a written quality agreement, verify the regulatory path for the actual product and market, and test whether the proposed source removes or merely duplicates existing dependencies. Use a risk-based depth of review; the controls should become more stringent as API production approaches final processing, purification and packaging.
Start by defining exactly what is being diversified
Before requesting documents or scheduling an audit, write a one-page scope statement. Identify:
- The API, dosage form and finished product it will support.
- Each destination market and the relevant marketing application, master file or other filing commitment.
- The intended manufacturing site, process steps, grade, specification and impurity profile.
- Whether the source is for routine commercial supply, contingency stock, development, a specific market or a limited capacity allocation.
- Every broker, distributor, repacker, contract laboratory, warehouse and other outsourced operation involved between the API manufacturer and your site.
- The incumbent source and the precise failure that diversification is meant to mitigate: quality failure, capacity shortage, geopolitical disruption, transport interruption, single-site dependence or another risk.
Confirm which legal entity actually manufactures the API and which sites perform synthesis, fermentation or cell culture, extraction, recovery, purification, micronization, packaging, testing and release. ICH Q7 covers these API manufacturing activities, subject to its stated scope and qualifications. Its supplier-approval expectations are described in the FDA-hosted guidance ICH Q7A.
#1 Best Overall
- Powerful Turbo Fan:CAGIWIRU Electric Air Duster have reached speed up to 130000RPM,Can efficient remove dust and debris.With LED light and Three Adjustable Speed to meet with different cleaning tasks.
- With Attached USB C Fasting Charging cable.Charing 3 hours,Enjoy up to 240 minutes of use on the lowest setting, For third speed can use for 25mins.with four charging options to meet with your needs.
- Wide Application: attached 5 different nozzles,making it suitable for a variety of scenes, such as car,pet, pc, keyboards, and other electronic devices. It also serves for office and home clean duster.
- Handy Design & Portable:Cordless air duster electric nozzle is Light weight and small size, design and comfortable to hold and space saving, convenient to carry around. You can put it in your room or inside the car without taking up space.
- Economical &Reusable: Built durable materials with a long-lasting battery,our CAGIWIRU air duster it's a sustainable alternative to disposable air cans.
Qualify the actual manufacturer, not just the commercial supplier
Demand evidence of consistent quality
Approval should be based on evidence that the named manufacturer can repeatedly meet the agreed specification. ICH Q7 states: “Supplier approval should include an evaluation that provides adequate evidence (e.g., past quality history) that the manufacturer can consistently provide material meeting specifications.” Review the site’s relevant quality history, audit results, regulatory inspection information where available, batch records, release data and history of rejected or reworked lots. The governing Q7 guidance is available from FDA at this page.
Examine the quality system and process capability
Tailor the review to the API’s hazards and process maturity. Evidence commonly includes:
- Quality-unit independence, authority and batch-disposition controls.
- Validated or otherwise scientifically justified process controls, cleaning controls and computerized systems.
- Deviation, out-of-specification (OOS), out-of-trend and laboratory-investigation procedures, including root-cause analysis and corrective and preventive action.
- Change control, data-integrity safeguards, record retention and traceability from starting materials through shipment.
- Complaint, return, recall and market-action procedures.
- Controls for critical starting materials, intermediates, solvents, catalysts, processing aids and outsourced testing.
- Training, preventive maintenance, calibration, environmental or contamination controls where relevant, and business-continuity arrangements.
This is an applied checklist rather than a universal FDA audit form. The depth should reflect the API’s toxicity, potency, route, impurity risks, process complexity, supply criticality and the consequences of failure. The FDA’s final September 2016 Q7 guidance for industry explains the applicable GMP framework.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteCheck comparability before calling the source interchangeable
A different synthesis route, polymorph, particle-size distribution, impurity profile, specification, site or critical raw material can affect formulation, stability, bioavailability, downstream processing or regulatory commitments. Technical and quality teams should compare the candidate and incumbent process descriptions, controls, analytical methods, impurity fate and purge, physical attributes and stability data. Q7 establishes the need to produce API meeting its intended quality and specifications; it does not provide a product-specific comparability conclusion. That conclusion requires data for the actual API, process and finished product.
Rank #2
- Screen Cleaner is Your Screen’s New Bestfriend! - EVEO is proud to present a screen cleaner that’s perfectly suited for your TV. Meet your new screen cleaner, computer screen cleaner, laptop cleaner, iPad cleaner, Macbook,tv cleaner or any other electronic device. Our screen cleaner spray and wipe along with the included plush microfiber cloth, easily removes dust, fingerprints & other smudges on the screen’s surface. Clean effectively for a streak-free screen
- Gentle on your Screens - Our screen cleaner spray and wipes is compatible to be used even for the most sensitive LCD, LED, CRT, and OLED screens in proper use. Be at ease knowing that this product is compatible with all the major brands: LG, SONY, Samsung, Sharp, iPad, iPhone, Android screens, Kindle, PC monitors - we’ve got you covered! Can be used as LCD screen cleaner, tv cleaner, smart tv screen cleaner, and more
- Premium Super Soft Plush Microfiber Cloth - Included in this efficient screen cleaning kit. This screen cleaner spray and wipe has our signature plush microfiber cloth specially designed to comply with screens and monitors and leave them streak-free. Has been shown to effectively absorbs stubborn stains, zero streaks, and no fiber shedding. Always use this together with our screen cleaner for the best results
- Easy-to-Use Screen Cleaner Kit + microfiber cleaning cloth - The EVEO Screen Cleaning Kit will easily be your new favorite tool when it comes to taking care of the things you love most, quick and easy solution for a streak-free screen. Simply screw on the sprayer gun on the screen cleaner bottle. Spray the cleaning liquid onto the microfiber cloth, then wipe the screen until desired cleanliness & shine is achieved.
- Quality Screen Care Kit Worth Purchasing - Enjoy a convenient Screen Cleaner anytime, anywhere you need it. Your satisfaction is our top priority. We stand behind the quality of our products and that’s why, you shouldn’t be worrying at all. We manufacture the Best Screen Cleaner. and can be used for laptop cleaning kit, laptop screen cleaner, tv screen cleaner for smart tv. MacBook screen cleaner, monitor cleaner or screen cleaner spray for electronic devices with microfiber cleaning cloth
Control receipt, sampling and supplier materials
Supplier approval belongs inside the material-control system, not in procurement alone. Q7 calls for written procedures covering receipt, identification, quarantine, storage, handling, sampling, testing, approval or rejection, and purchasing to agreed specifications from suppliers approved by the quality unit. Translate those requirements into operating instructions for your receiving, warehouse, laboratory and quality teams.
Define how containers are inspected, labels and seals are verified, lots are identified, samples are taken without contamination, temperature or humidity excursions are handled, and material is released to production. Specify what happens when a shipment arrives from an unapproved site, through an unapproved intermediary or with incomplete documentation. The procedure should make it impossible for a purchasing substitution to bypass quality-unit approval.
Build an analytical qualification and COA-reliance plan
Agree the testing model before routine orders
Set the specification, analytical methods, acceptance limits, sampling plan, reference standards, method-transfer or verification work, impurity characterization and handling of discrepant results before the first commercial shipment. Decide which tests your laboratory will perform, which results may be accepted from the supplier’s certificate of analysis (COA), and how results will be reconciled when the two laboratories disagree.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Meet the identity-test and reliability requirements
When a finished-drug manufacturer relies on an API supplier’s analysis, FDA requires at least one specific identity test and requires the manufacturer to validate the reliability of the supplier’s analyses at appropriate intervals. FDA states: “Therefore, if the finished drug product manufacturer accepts the test results from an API supplier’s COA rather than performing the tests itself (other than for identity, which the manufacturer is required to perform), the manufacturer must validate the API supplier’s reliability.” The statement appears in FDA’s June 9, 2015 CGMP questions and answers on control of components.
Rank #3
- 【Large size】：Measuring 800 x 300 mm/ 31. 5×12 inches, which is wider and taller than others. Large mouse pad can perfectly fit your keyboard and mouse of any size, and there is also ample space for peripherals such as phones, tablets, etc.
- 【LED backlight mouse pad】：Blade Hawks RGB mouse pad provides 7 static modes and 7 dynamic modes will give you the options you are looking for. Power-off memory function remembers the last lighting mode you selected. The super glow fiber Chroma will give you a colorful gaming setup that you want.
- 【Anti-slip rubber base】：Made from Natural rubber, this gaming mousepad will firmly grip your desktop, allowing you to enjoy the ultimate precision in the games you are most passionate about. It also comes with a texture that enhances this ability even further.
- 【Smooth and waterproof surface】: Micro-textured cloth surface, for extremely precise mouse control and a smooth movement. When liquid splashes on the gaming mouse pad, it forms water droplets and slides down. Will not delay your work or gameplay.
- 【Plug and play】: This mouse and keyboard pad is powered by USB, plug and play, no driver required. One button control light modes. Press one time to change the lighting mode, press twice to change the brightness, press and hold about 3 seconds turn ON/OFF.
Use the three-batch recommendation correctly
Q7 recommends complete analysis of at least three batches before reducing in-house testing, followed by complete analysis at appropriate intervals in comparison with supplier COAs and regular verification of COA reliability. Treat “three batches” as the Q7 recommendation for establishing confidence, not as a universal waiver from applicable CGMP, filing commitments or your product-specific control strategy. Document the scientific rationale, test frequency, trend review, reversion triggers and approval by the quality unit.
Put operating responsibilities in a written quality agreement
Use a quality agreement with the manufacturer and, where appropriate, with contract laboratories or other contract facilities. Keep commercial terms separate or severable from quality terms so that a price or volume dispute cannot obscure a safety or compliance obligation.
Define the subjects that cause real failures
Cover, at minimum:
- Manufacturing, laboratory, sampling, packaging, storage and release/disposition responsibilities.
- Batch records, certificates, electronic data, retention samples and record-access rights.
- Deviation, OOS, complaint, recall and investigation ownership, timelines and escalation contacts.
- Planned and unplanned changes, regulatory-impact assessments and advance-notification or approval requirements.
- Subcontracting, approved-site lists and controls over further delegation.
- Audit rights, inspection support, response to findings and corrective-action verification.
- Communication routes for shortages, allocation, transport incidents, data-integrity concerns and quality emergencies.
FDA’s final November 2016 Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry recommends documenting these CGMP-related roles. It also makes the legal boundary explicit: “Quality agreements cannot be used to delegate statutory or regulatory responsibilities to comply with CGMP.” The agreement allocates work; it does not transfer the manufacturer’s continuing obligations.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minutePlan ongoing oversight and requalification
Qualification is a continuing state, not a one-time questionnaire. Establish a supplier-specific review cadence and retain evidence that the source remains suitable. A practical scorecard can include:
Rank #4
- 【Softer and More Comfortable】Vaydeer wrist rest has unique diamond pattern, which is the combination of softness and aesthetics. The materials of wrist rest are improved into higher quality memory foam and covered with silky smooth lycra. The computer wrist rest makes you as comfortable and cushiony as like rest your wrists on clouds.
- 【Ergonomic Wrist Saver】The wrist rests for keyboard and mouse comes with a 17.32×3.15×0.83 inch keyboard wrist pad and a 5.94×3.15×0.83 inch mouse wrist support. Based on ergonomic design, the unique concave shape is the perfect fit for your wrist joints. The wrist rest pad fits most computer keyboards and laptops, improve hand and wrist posture, release your wrist and arm stress.
- 【Non-Slip Rubber Bottom】Featuring an anti-skid silicone base on the bottom, this wrist keyboard support stays firmly in place on your desk, preventing the padding from sliding around, ensuring stable and consistent wrist support during extended computer sessions.
- 【Better Experience & Pain Relief】Our keyboard arm rest is beneficial to alleviate the soreness caused by direct contact and friction between your arm and a hard desk surface, reducing the risk of wrist fatigue or carpal tunnel. The soft texture of memory foam can evenly distribute the pressure around your wrists and provide good support with just enough give.
- 【Helpful in Multiple Scenarios】Whether you're working, studying, writing, typing, gaming, this keyboard and mouse rest combo is an essential accessory to add comfort and support to your hands and wrists. It’s also a great gift for men, women, family, friend, coworker, gamer, teacher, etc.
- Accepted, rejected and late lots; deviations; OOS and out-of-trend investigations.
- Audit findings, overdue corrective actions and repeat observations.
- Completeness and timeliness of COAs, batch records, change notices and other documentation.
- Complaints, returns, recalls, regulatory observations and data-integrity signals.
- On-time delivery, lead-time variability, allocation events, minimum-order constraints and interruption duration.
- Use of approved manufacturing, testing, distribution and repackaging sites.
Set escalation thresholds and requalification triggers according to product criticality and risk appetite rather than copying an invented industry score. FDA’s quality-agreement guidance discusses ICH Q10 oversight and purchased-material controls and supports pre-selection assessment, ongoing performance review and improvement; the same guidance is available at FDA’s quality-agreements document.
Reassess after a major process, site, ownership, specification, analytical-method, subcontractor or upstream-material change; a significant deviation or recall; repeated delivery failures; or a prolonged period without supply. Verify that incoming material still comes through the approved supply chain, not merely from an approved company name.
Test whether the second source actually reduces correlated risk
Map the full dependency chain
For both incumbent and candidate sources, map API starting materials, key intermediates, critical reagents, manufacturing and testing sites, ownership and contract relationships, distributors, repackers, warehouses, transport lanes, ports, utilities and other dependencies relevant to the product. Ask where the two sources share a starting-material producer, a specialized laboratory, a port, a packaging component, a utility, a region exposed to the same hazard or a parent company’s allocation policy.
Compare failure scenarios, not just locations
Model realistic events: a quality-system shutdown, contamination, fire, cyber incident, export restriction, natural disaster, utility failure, transport blockage, starting-material shortage, laboratory loss or sudden demand allocation. Estimate capacity, lead time, safety stock, recovery time, substitution constraints and the time required to qualify or release material. Geographic separation can help, but it does not by itself prove independence.
Best Value
- 【No Drill Mounted】Cable management tray can be assembled in as little as 3 minutes or less-simply. Side clips easily clampe the edge of desk, pass through the holes on the sides, and secure excess cables with baskets. Desk cable management supports inward or outward installation to meet your needs in different scenarios, and provides you with great convenience when collecting and organizing wires.
- 【Rubber Pad Protects Desk】Wire organizer under desk built-in soft rubber pads on the clamp protect your desk from scratches, so you will not damage your furniture or office.
- 【Sturdy and Beautiful】Cord management under desk is made of high-quality carbon steel and holds about 15 lbs. The wire basket has 2 holes on each side of the tray to enable your cables to pass freely. Cable baskets are suitable for desk thickness use from 0.4" to 2.4".
- 【Space Saving & Keep Organized】Desk cable management tray holds all your power cords, outlet strips, USB hubs and computer transformers hidden from your feet, and the data cables will not enter the vacuum cleaner to keep your desk clean and tidy. Desk wire organizer is also suitable for use in the kitchen and outdoors.
- 【Reduce Safety Risks】Cable tray under desk keeps all plugs away from your kids, no more worry about tripping. Using 2 holes wire tray saves extra space, helps you easily cabling and wire protection. The mesh design is not easy to accumulate dust, but avoids safety accidents caused by messy wires.
FDA’s May 2022 Risk Management Plans to Mitigate Potential Drug Shortages offers a planning framework for identifying, prioritizing and mitigating hazards that can cause disruption. It is explicitly marked “Draft” and “Not for implementation,” so use it as a planning reference rather than binding regulation. The draft says, “Based on recent publications and reports, the majority of drug shortages are associated with quality issues.” It gives no percentage on the cited page; do not convert that statement into a numeric shortage statistic.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Compare viable candidates with a documented framework
Use a cross-functional team from quality, regulatory affairs, technical operations, procurement, supply chain, manufacturing and finance. Document the weights for each API and product instead of applying a universal formula.
| Comparison axis | Questions to answer | Evidence or output |
|---|---|---|
| Quality history and GMP capability | Can the named site repeatedly meet specifications with effective investigations and CAPA? | Quality history, audit or equivalent evaluation, inspection information, batch and investigation records |
| Technical and analytical fit | Are route, impurity profile, physical attributes, methods and specifications suitable? | Process comparison, method qualification or transfer plan, impurity and stability assessment |
| Regulatory readiness | Can the source be used under the product’s actual application and market commitments? | Documented regulatory-impact assessment and submission strategy |
| Upstream and geographic dependency | Does the source share critical materials, sites, lanes or ownership with the incumbent? | Dependency map and correlated-failure analysis |
| Capacity and allocation risk | What capacity, lead time, flexibility, inventory and recovery time are credible? | Capacity evidence, supply plan, allocation terms and continuity assumptions |
| Logistics and traceability | Can every shipment be traced through approved intermediaries and controlled conditions? | Approved-route map, shipping controls, temperature or security records where relevant |
| Oversight workload and transparency | How quickly and completely will the supplier report changes, deviations and risks? | Quality agreement, communication matrix, audit schedule and performance scorecard |
| Total landed cost | What is the complete cost after testing, qualification, inventory, freight, duties, rejects and dual-source overhead? | Documented cost model; no universal benchmark applies |
Confirm the regulatory path for the specific product
Do not infer a filing category, approval timeline or notification requirement from the fact that a second supplier is being added. Regulatory affairs must review the product’s marketing application, currently registered API source and site, process and specification commitments, proposed changes and destination jurisdictions. Determine whether the change requires a submission, prior approval, notification or another action under the applicable rules.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
FDA’s Q7 guidance expressly says it is not intended to define registration or filing requirements and that commitments in registration or filing documents should be met. The final September 2016 guidance is at FDA’s Q7 page. For decisions outside the United States, verify the requirements of the relevant regulator; FDA and ICH materials do not automatically determine another jurisdiction’s filing obligations. The regulatory consequence cannot be resolved without the actual application, registered source and site, change details, commitments and markets.
A practical approval sequence
- Write the scope and risk question. Name the API, product, markets, sites, intermediaries and the disruption the second source should address.
- Collect a site-level information package. Obtain process, specifications, quality history, audit evidence, upstream-source information, capacity data and regulatory details.
- Perform a risk-based quality and technical assessment. Escalate to an audit or equivalent evaluation when the API’s risk, history or evidence warrants it.
- Complete comparability and analytical planning. Approve methods, sampling, identity testing, COA reliance, initial full testing and ongoing verification before routine supply.
- Approve the quality agreement. Assign responsibilities, change notification, subcontracting controls, records, escalation and audit rights.
- Resolve the product-specific regulatory path. Obtain the required internal and external approvals before commercial use.
- Run qualification batches and release them under the approved controls. Investigate every discrepancy and trend results against the incumbent where appropriate.
- Activate the ongoing scorecard and continuity plan. Review quality, service, dependency and change data at a defined cadence and trigger requalification when conditions change.
Common diversification mistakes
- Counting suppliers instead of independent paths: two vendors may share the same starting material, site or logistics bottleneck.
- Approving a distributor without identifying the manufacturer: the quality decision must cover the actual manufacturing and testing sites.
- Treating a COA as a substitute for qualification: identity testing and validation of supplier analytical reliability remain necessary when relying on supplier results.
- Using a quality agreement to shift accountability: contracts allocate activities but cannot delegate statutory or regulatory CGMP responsibilities.
- Reducing testing without documented evidence: the Q7 three-batch recommendation still requires a justified, approved verification program.
- Assuming a different country guarantees resilience: shared upstream materials, ownership, ports or utilities can create common-cause failure.
- Leaving regulatory review until after purchasing: a technically acceptable API may still require a filing action before commercial manufacture.
- Choosing on unit price alone: qualification, testing, inventory, freight, rejects, dual oversight and interruption costs belong in the landed-cost decision.
A second API source is worth approving when the site can demonstrate consistent quality, the material and process fit the product, responsibilities and changes are controlled, the regulatory path is clear, and the dependency analysis shows a meaningful reduction in correlated disruption risk. If any of those conditions remains unresolved, treat the source as an unqualified contingency—not as an operationally available supplier.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
